Ventyx Biosciences (NASDAQ:VTYX) Given Market Perform Rating at Lifesci Capital

Ventyx Biosciences (NASDAQ:VTYX)‘s stock had its “market perform” rating reiterated by stock analysts at Lifesci Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $14.00 price objective on the stock. Lifesci Capital’s target price points to a potential upside of 1.97% from the stock’s current price.

VTYX has been the subject of a number of other reports. HC Wainwright upgraded shares of Ventyx Biosciences from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a report on Wednesday, November 5th. Wells Fargo & Company lifted their price target on Ventyx Biosciences from $11.00 to $14.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Oppenheimer boosted their price objective on Ventyx Biosciences from $9.00 to $14.00 and gave the stock an “outperform” rating in a report on Monday, October 27th. UBS Group reissued a “neutral” rating and issued a $14.00 price objective (down from $20.00) on shares of Ventyx Biosciences in a research note on Thursday. Finally, Canaccord Genuity Group reaffirmed a “hold” rating and set a $14.00 target price (down previously from $16.00) on shares of Ventyx Biosciences in a research report on Thursday. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Ventyx Biosciences has a consensus rating of “Hold” and an average price target of $14.67.

Ventyx Biosciences Stock Up 36.6%

NASDAQ VTYX opened at $13.73 on Thursday. Ventyx Biosciences has a 52 week low of $0.78 and a 52 week high of $25.00. The business has a 50 day moving average price of $9.05 and a 200-day moving average price of $5.14. The company has a market cap of $979.77 million, a price-to-earnings ratio of -9.15 and a beta of 1.23.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.13. On average, equities research analysts anticipate that Ventyx Biosciences will post -2.09 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO Raju Mohan sold 47,345 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John Nuss sold 12,675 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $7.72, for a total value of $97,851.00. Following the completion of the transaction, the insider directly owned 489,481 shares of the company’s stock, valued at approximately $3,778,793.32. This represents a 2.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 14.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Affinity Asset Advisors LLC bought a new position in Ventyx Biosciences in the 2nd quarter worth approximately $9,707,000. Vanguard Group Inc. lifted its position in shares of Ventyx Biosciences by 19.2% during the third quarter. Vanguard Group Inc. now owns 3,769,997 shares of the company’s stock worth $11,725,000 after acquiring an additional 607,725 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Ventyx Biosciences in the second quarter worth $5,129,000. Vestal Point Capital LP boosted its holdings in shares of Ventyx Biosciences by 2.5% in the third quarter. Vestal Point Capital LP now owns 2,050,000 shares of the company’s stock worth $6,376,000 after acquiring an additional 50,000 shares during the period. Finally, Millennium Management LLC grew its position in shares of Ventyx Biosciences by 17.5% in the third quarter. Millennium Management LLC now owns 1,651,794 shares of the company’s stock valued at $5,137,000 after purchasing an additional 246,040 shares in the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.